It has been the talk of the industry for the last year and finally the 6CPA has been signed and approved.
If you have been keeping up with the media, you may already know a few things about the Agreement and if you've been brave, you've even read the Agreement itself.
To make things easier, our national team have put together some facts about the 6CPA to give you a better understanding of how things will work for the next five years:
If you have been keeping up with the media, you may already know a few things about the Agreement and if you've been brave, you've even read the Agreement itself.
To make things easier, our national team have put together some facts about the 6CPA to give you a better understanding of how things will work for the next five years:
The top 10 benefits of the Sixth Community Pharmacy Agreement
1. The 6CPA increases the Government’s investment in community pharmacy by $2.4 billion over 5 years ($2.8 billion including chemotherapy) compared with the forward estimates before the agreement was negotiated.
2. Average dispensing remuneration will be $1.13 more per prescription in 2015-16 than it would have been without the 6CPA, rising to $2.19 more in 2019-20 than it would have been without the 6CPA.
3. With the 6CPA, average per script remuneration will increase every year from 2015-16 to 2019-20. Without the 6CPA, average per script remuneration in 2019-20 would be lower than 2014-15.
4. There will be a significant immediate increase in dispensing remuneration from 1 July 2015 with the introduction of the AHI at a minimum of $3.49 per script, a 17c increase in the dispensing fee, a 4c increase in the PFDI and a 20c increase in the dangerous drug fee.
5. The AHI means that for the first time pharmacies’ official dispensing remuneration will be virtually immune from the impact of price disclosure. The AHI puts a permanent floor on dispensing remuneration.
6. For the first time, all the main elements of dispensing remuneration, including the dispensing fee, the AHI, PFDI and the dangerous drug fee will be indexed annually to CPI so that their value is maintained throughout the 6CPA in real terms.
7. The value of the PFDI will be maintained in real terms.
8. For the first time, pharmacies will be directly remunerated for the provision of diabetes products under the NDSS.
9. Additional funding for chemotherapy has been secured until mid-2020 from outside the 6CPA envelope.
10. The Location Rules will be extended until mid-2020. No changes can be made to the Location Rules during the 6CPA without the express agreement of the Guild.
Still unsure? Visit our national website for more details.
1. The 6CPA increases the Government’s investment in community pharmacy by $2.4 billion over 5 years ($2.8 billion including chemotherapy) compared with the forward estimates before the agreement was negotiated.
2. Average dispensing remuneration will be $1.13 more per prescription in 2015-16 than it would have been without the 6CPA, rising to $2.19 more in 2019-20 than it would have been without the 6CPA.
3. With the 6CPA, average per script remuneration will increase every year from 2015-16 to 2019-20. Without the 6CPA, average per script remuneration in 2019-20 would be lower than 2014-15.
4. There will be a significant immediate increase in dispensing remuneration from 1 July 2015 with the introduction of the AHI at a minimum of $3.49 per script, a 17c increase in the dispensing fee, a 4c increase in the PFDI and a 20c increase in the dangerous drug fee.
5. The AHI means that for the first time pharmacies’ official dispensing remuneration will be virtually immune from the impact of price disclosure. The AHI puts a permanent floor on dispensing remuneration.
6. For the first time, all the main elements of dispensing remuneration, including the dispensing fee, the AHI, PFDI and the dangerous drug fee will be indexed annually to CPI so that their value is maintained throughout the 6CPA in real terms.
7. The value of the PFDI will be maintained in real terms.
8. For the first time, pharmacies will be directly remunerated for the provision of diabetes products under the NDSS.
9. Additional funding for chemotherapy has been secured until mid-2020 from outside the 6CPA envelope.
10. The Location Rules will be extended until mid-2020. No changes can be made to the Location Rules during the 6CPA without the express agreement of the Guild.
Still unsure? Visit our national website for more details.
